Alzheimer's Disease Trial, Recruiting NCT03799991 Sponsor: Johns Hopkins University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT03799991
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Alzheimer's disease that is mild to moderate in severity (based on a standard medical rating scale).
  • You are 60 years old or older.
  • You have reduced or impaired function in both of your inner ears (the parts that help control balance).
  • You are able to take part in study activities, including balance tests, walking assessments, memory and thinking tests, and a balance training program.
  • You are able to understand and agree to take part in the study on your own (give informed consent).
  • You have a caregiver — someone who spends at least 10 hours per week with you — who is also able to take part in some study activities, including receiving text message updates.

Who may not be able to join:

  • You have been diagnosed with severe Alzheimer's disease (based on a standard medical rating scale).
  • You have mild memory or thinking problems that do not meet the criteria for Alzheimer's disease, or you have a different type of dementia (such as Parkinson's disease dementia, Lewy body dementia, vascular dementia, or others).
  • You are unable to take part in study activities due to serious health conditions, significant agitation, or because you use a walking aid such as a cane or walker.
  • You take certain daily medications for dizziness or balance (specifically antihistamines or benzodiazepines), as these can affect how the body responds to balance training.
  • You are not available to attend the full 8-week program of weekly visits and daily home exercises.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yuri Agrawal, MD, Johns Hopkins University

Phone: 4105023107

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 August 2022
Est. completion
26 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participant falls

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov